L3VLUP
ProSign in

ENTA in the 13F filings

Enanta Pharmaceuticals Inc · CUSIP 29251M106

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
31 Mar 2024
the date the book describes
Filed
24 May 2024
latest of these filings; the earliest 10 May 2024
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q4 2023 and Q1 2024; 3 listed it in both
Shares listed
2,988,623
combined, among listed positions
Reported value
$52m
combined, at the quarter end

Among the 93 comparable managers: 2 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares was +57,454.

Managers listing ENTA in Q1 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q4 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Farallon Capital Management LLC2,095,000$37m0.16%Added+70,00024 May 2024 (the filing on sec.gov)
Acadian Asset Management LLC853,896$15m0.05%Added+10,95210 May 2024 (the filing on sec.gov)
PDT Partners LLC39,727$694k0.07%Trimmed-23,49815 May 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q4 2023 to Q1 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q3 2024 to 3 in Q2 2026

Tracked managers listing it, at least.

035810201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ENTA by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20142$13mn.a.n.a.
Q4 20141$9.9mn.a.n.a.
Q1 20152$8.3mn.a.n.a.
Q2 20151$12mn.a.n.a.
Q3 20151$27mn.a.n.a.
Q4 20151$27mn.a.n.a.
Q1 20162$24mn.a.n.a.
Q2 20162$16mn.a.n.a.
Q3 20162$10mn.a.n.a.
Q4 20161$19mn.a.n.a.
Q1 20172$8.4mn.a.n.a.
Q3 20172$20mn.a.n.a.
Q4 20172$100mn.a.n.a.
Q1 20187$184mn.a.n.a.
Q2 20187$291mn.a.n.a.
Q3 20185$186mn.a.n.a.
Q4 20186$159mn.a.n.a.
Q1 20196$287mn.a.n.a.
Q2 20194$208mn.a.n.a.
Q3 20195$126mn.a.n.a.
Q4 20197$174mn.a.n.a.
Q1 20209$191mn.a.n.a.
Q2 20208$178mn.a.n.a.
Q3 20206$163mn.a.n.a.
Q4 20206$144mn.a.n.a.
Q1 20216$170mn.a.n.a.
Q2 20215$143mn.a.n.a.
Q3 20214$171mn.a.n.a.
Q4 20214$183mn.a.n.a.
Q1 20225$163mn.a.n.a.
Q2 20223$74mn.a.n.a.
Q3 20222$80mn.a.n.a.
Q4 20222$72mn.a.n.a.
Q1 20232$63mn.a.n.a.
Q2 20232$41mn.a.n.a.
Q3 20234$28mn.a.n.a.
Q4 20233$28m22
Q1 20243$52m21
Q2 20243$39m02
Q3 20242$31m10
Q4 20241$12m00
Q1 20252$12m20
Q2 20252$17m01
Q3 20253$37m01
Q4 20254$118m186
Q1 20262$84m1111
Q2 20263$104m713

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ENTA and LLY →ENTA and JNJ →ENTA and VRTX →Choose a stock to compare with ENTA →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ENTA, latest filings →Back to the 13F Explorer →